Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry S Wolinsky

Showing results (61-70 of 139) with videos related to

Pageof 14
Sort By:
European Journal of Neurology|March 16, 2021
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trialsGavin Giovannoni, Ludwig Kappos, Jerome de Seze, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 21, 2005
Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study groupMassimo Filippi, Andrea Falini, Douglas L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 21, 2003
Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trialsFilippo Martinelli Boneschi, Marco Rovaris, Kenneth P Johnson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 13, 2018
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trialEdward J Fox, Clyde Markowitz, Angela Applebee, et al.
Clinical Trials (London, England)|April 2, 2014
Recruitment of participants to a multiple sclerosis trial: the CombiRx experienceMinal J Bhanushali, Tarah Gustafson, Steve Powell, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2017
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data setMarcus W Koch, Gary R Cutter, Gavin Giovannoni, et al.
Journal of Neuroimmunology|November 26, 2018
Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosisNatalia P Rocha, Gabriela D Colpo, Javiera Bravo-Alegria, et al.
Annals of Neurology|January 31, 2007
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trialJerry S Wolinsky, Ponnada A Narayana, Paul O'Connor, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2016
Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosisFlavia Nelson, Mohammad A Akhtar, Edward Zúñiga, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 yearsFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Pageof 14

Showing results (61-70 of 139) with videos related to

Sort By:
Pageof 14
European Journal of Neurology|March 16, 2021
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trialsGavin Giovannoni, Ludwig Kappos, Jerome de Seze, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 21, 2005
Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study groupMassimo Filippi, Andrea Falini, Douglas L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 21, 2003
Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trialsFilippo Martinelli Boneschi, Marco Rovaris, Kenneth P Johnson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 13, 2018
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trialEdward J Fox, Clyde Markowitz, Angela Applebee, et al.
Clinical Trials (London, England)|April 2, 2014
Recruitment of participants to a multiple sclerosis trial: the CombiRx experienceMinal J Bhanushali, Tarah Gustafson, Steve Powell, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2017
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data setMarcus W Koch, Gary R Cutter, Gavin Giovannoni, et al.
Journal of Neuroimmunology|November 26, 2018
Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosisNatalia P Rocha, Gabriela D Colpo, Javiera Bravo-Alegria, et al.
Annals of Neurology|January 31, 2007
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trialJerry S Wolinsky, Ponnada A Narayana, Paul O'Connor, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2016
Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosisFlavia Nelson, Mohammad A Akhtar, Edward Zúñiga, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 yearsFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Pageof 14